Navigation Links
Upsher-Smith Announces Commercial Availability Of Morphine Sulfate ER Capsules
Date:8/29/2013

MAPLE GROVE, Minn., Aug. 29, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc., today announced its Morphine Sulfate Extended-Release Capsules, CII will be commercially available on September 4, 2013.

(Logo:  http://photos.prnewswire.com/prnh/20130520/NY17281LOGO )

Historically, there have been a limited number of morphine sulfate generics available.  Upsher-Smith used its extensive formulation experience to overcome the challenges presented.

Upsher-Smith's family of Morphine Sulfate Extended-Release Capsules, CII includes seven dosage strengths: 10 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg, and 100 mg.  This will be the first generic entrant for the 10-mg extended-release capsule dosage strength.1 Upsher-Smith's generic drug segment is dedicated to providing high-quality pharmaceutical products that are affordable and accessible to patients.

About Upsher-Smith
Upsher-Smith is an independent specialty pharmaceutical company dedicated to its mission of Advancing Pharmacotherapy to Improve Life™. Upsher-Smith currently leverages its core strength in formulation development to drive both branded and generic therapeutic solutions to address patients' needs ranging in scope from women's health to cardiology. The Company has a particular focus on developing therapies for people living with challenging central nervous system conditions like epilepsy, and has an emerging neurology pipeline with three products in clinical development.  For more information, visit www.upsher-smith.com.

Please see Full Prescribing Information, including Boxed Warning, at http://www.upsher-smith.com/wp-content/uploads/MorphineSulfate_MI.pdf.

References
1. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. http://www.accessdata.fda.gov/scripts/cder/ob/docs/tempai.cfm.  Accessed May 9, 2013.


'/>"/>
SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Upsher-Smith Teams Up With Epilepsy Foundation Of Minnesota For 2013 Stroll For Epilepsy
2. Upsher-Smith Announces Patient Enrollment In Open-label Safety Study Of USL261 (Intranasal Midazolam) For Rescue Treatment Of Seizure Clusters In Epilepsy
3. Upsher-Smith Is Honored With Prestigious Industry Award For Leadership And Innovation
4. Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures
5. Upsher-Smith Introduces Newly Redesigned Corporate Website
6. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
7. Emerging Data From Upsher-Smiths CNS Portfolio Highlighted At 2013 American Academy Of Neurology Meeting
8. Doug Zitnak of Upsher-Smith Laboratories Named Small Brand Manufacturer Representative of the Year By Cardinal Health
9. Tina Fehr, Senior Product Manager For AmLactin, Upsher-Smith Laboratories Named PM360 Trailblazer Winner For Womens Health Brand Manager
10. Upsher-Smith Teams Up With Epilepsy Foundation of Minnesota for 2012 Stroll for Epilepsy
11. Upsher-Smith Is Honored with Prestigious Industry Award for Excellence and Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... 12, 2017  Eli Lilly and Company (NYSE: ... companies to resolve pending patent litigation in the U.S. District ... regarding the Cialis ┬« (tadalafil) unit dose patent. ... 2020. As part of the agreement, Cialis exclusivity is now ... "The unit dose patent for Cialis is valid ...
(Date:7/11/2017)...  Sysmex America, Inc., a leading provider of ... well as middleware information systems technology, today announced ... assurance easier and more risk free than manual ... the innovation that it delivers to the laboratory. ... processes to a new level with automated, continuous ...
(Date:7/10/2017)... Md. , July 10, 2017 The ... non-animal test methods, is the recipient of a VITROCELL® ... the PETA International Science Consortium. The device, which is ... used to expose human lung cells to airborne test ... IIVS will use the VITROCELL® system for testing combustible ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... SignatureCare Emergency Center ... be awarded for the fall semester to a deserving student. Get your applications ... 2017 scholarship was awarded to Mariana Castillo who is a nursing student at Prairie ...
(Date:7/24/2017)... Los Angeles, California (PRWEB) , ... July 24, ... ... office building fire in Oakland, California effectively destroyed the construction site and threatened ... to a July 7th article on NBCLosAngeles.com. Los Angeles Area ...
(Date:7/24/2017)... ... July 24, 2017 , ... Axiad IDS , ... announced it has partnered with WALLIX to expand its solution to help ... , There are a number of ways to address the authentication requirements within ...
(Date:7/24/2017)... ... July 24, 2017 , ... Puregraft, the global ... the issuance of United States Patent Number 9,695,398 (the '398 patent) and South ... The '398 and '324 patents cover methods and systems for optimizing fat grafts ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... solution focused on delivering end-to-end sleep health care at scale, indicates record-breaking ... shows that adherence rates for positive airway pressure (PAP) therapy, the most widely ...
Breaking Medicine News(10 mins):